Astrazeneca Plc (AZN) 47.29 -0.33

AstraZeneca PLC ADS
(AZN) 47.29 -0.33

Last Trade:	47.16	Day Range:	46.87 - 47.19
Trade Time:	04:02PM	52wk Range:	40.89 - 52.47
Prev. Close:	47.49	Market Cap:	62.27B
Open:	46.96	Div Yield:	3.6
Volume:	1267670	PE:
EPS:	0.00

The Latest On AZN

Three Conservative Stocks To Play The Stock Market Rally 2/8/12 4:02pm

Notable Put Options Activity in AstraZeneca 2/2/12 11:24am

AstraZeneca To Cut 7,300 Jobs, Projects Drop In Profit 2/2/12 4:52am

From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin 1/19/12 7:10am

Notable Call Options Activity in AstraZeneca 1/18/12 10:47am

Market Roundup 1/9/12 11:35am

AstraZeneca Reaffirms 2011 Earnings Forecast 1/9/12 6:57am

ETF Showdown: Fun With Pharma 12/30/11 4:10pm

Notable Put Options Activity on AstraZeneca 12/28/11 2:57pm

AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder 12/20/11 7:38am

Citi Reiterates Neutral On AstraZeneca 12/19/11 11:50am

AstraZeneca Announces Share Repurchase Programme 12/15/11 11:31am

Three Conservative Stocks To Play The Stock Market Rally 2/8/12

Notable Put Options Activity in AstraZeneca 2/2/12

AstraZeneca To Cut 7,300 Jobs, Projects Drop In Profit 2/2/12

From Earlier: Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin 1/19/12

Notable Call Options Activity in AstraZeneca 1/18/12

Market Roundup 1/9/12

AstraZeneca Reaffirms 2011 Earnings Forecast 1/9/12

ETF Showdown: Fun With Pharma 12/30/11

Notable Put Options Activity on AstraZeneca 12/28/11

AstraZeneca and Targacept Announce Top-line Results from Second Phase 3 Study of TC-5214 as an Adjunct Treatment in Patients with Major Depressive Disorder 12/20/11

Citi Reiterates Neutral On AstraZeneca 12/19/11

AstraZeneca Announces Share Repurchase Programme 12/15/11

Three Conservative Stocks To Play The Stock Market Rally 2/8/12

ETF Showdown: Fun With Pharma 12/30/11

Citi Reiterates Neutral On AstraZeneca 12/19/11

Is Endo Pharmaceuticals Going to Seize Market Share? 12/12/11

Financial Breakfast: Morning News Summary for November 8, 2011 11/8/11

Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS 10/24/11

Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS 10/13/11

Bristol-Myers Squibb Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter 7/25/11

AstraZeneca Spikes on Brilinta Approval Rumor, Continues to Rise Following FDA Confirmation 7/20/11

News Summary for July 1, 2011 7/1/11

News Summary for June 22, 2011 6/22/11

News Summary for June 21, 2011 6/21/11

Citi Reiterates Neutral On AstraZeneca 12/19/11

Citigroup Initiates AstraZeneca at Neutral 11/29/11

End-of-Day Market Summary for November 16, 2011 11/16/11

Financial Breakfast: Morning News Summary for November 8, 2011 11/8/11

Jefferies Rating and PT Updates 8/4 8/4/11

Jefferies Upgrades AstraZeneca To Hold 8/4/11

Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca 6/27/11

Wells Fargo Initiating Coverage On RIGL With An Outperform Rating And A $10-12 Valuation Range 12/10/10

Credit Suisse Downgrades AZN To Underperform 12/7/10

Benzinga's Top Downgrades (AZN, SM, TKC, MFE) 9/29/10

AstraZeneca Falls On Downgrade In Rating 9/29/10

Standpoint Research Downgrades AstraZeneca (NYSE:AZN) 7/29/10

Trade AZN
NOW!

Partner Headlines

Ten Big Pharma Stocks' Juicy Dividend Payouts, With Cash-on-Hand as Cushion 2/8/12

Higher Bleeding Haunts Merck Candidate - Analyst Blog 2/8/12

Layoffs Continue to Mount 2/8/12

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Eli Lilly, Johnson & Johnson, Pfizer and AstraZeneca - Press Releases 2/7/12

AZN Beats Estimates by a Whisker - Analyst Blog 2/6/12

Gilead EPS Misses, Share Dip 2/2/12

Stock Futures Climb; Cummins Gains On Q4 Beat 2/2/12

Billion Dollar Quarterly Research & Development Club: Who Turns R&D Into Stockholder Gains? 2/1/12

Ken Fisher and the Price to Research Ratio 2/1/12

Big Buys In Share Buybacks (PKW, TTFS, AMGN, AZN, MSFT) 1/27/12

Bristol Myers Q4 Profit, Sales Below Expectations 1/26/12

Press Releases

AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs 2/8/12 Business Wire Story

AstraZeneca Recognized as a Top Company for Female Executives 2/7/12 Business Wire Story

AstraZeneca, United Way of Delaware Kick Off Statewide Youth Health Initiative 1/20/12 Business Wire Story

Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin 1/19/12 Business Wire Story

Critical Alerts for Wal-Mart, BP, AstraZeneca, HCP, and Varian Medical Released by Seven Summits Research 1/5/12 Newswire Story

New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment 12/8/11 Business Wire Story

AstraZeneca to streamline US Sales Organization 12/7/11 Business Wire Story

Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes 11/16/11 Business Wire Story

SATURN Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis 11/15/11 Business Wire Story

INSERTING and REPLACING BRILINTA™ (ticagrelor) Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI 11/7/11 Business Wire Story

BRILINTA™ (ticagrelor) Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI 11/7/11 Business Wire Story

New CRESTOR® (rosuvastatin calcium) Savings Card Program Provides Instant Savings to Patients 11/7/11 Business Wire Story

Get the latest AZN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for AstraZeneca PLC ADS stock price.

AstraZeneca PLC ADS by YCharts

Astrazeneca Plc (AZN) 47.29 -0.33

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On AZN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social